Literature DB >> 31347138

Epidemiological and etiological variations in hepatocellular carcinoma.

Evangelista Sagnelli1, Margherita Macera2, Antonio Russo2, Nicola Coppola2, Caterina Sagnelli2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer and a leading cause of cancer-related deaths worldwide. The major risk factors for HCC development are chronic liver disease and cirrhosis due to hepatitis B virus (HBV) and/or hepatitis C virus (HCV), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, intake of aflatoxin-contaminated food, diabetes, and obesity.
RESULTS: In Western countries, the number of NASH-related HCC cases is increasing, that of HBV- or HCV-related cases is declining due to the wide application of HBV universal vaccination and the introduction of effective therapies against HBV and HCV infections, and that of alcohol-related cases remaining substantially unchanged. Nevertheless, the burden of HCC is expected to increase worldwide in the next few decades, due to the population growth and aging expected in coming years. Overall, the abovementioned changes and future variations in lifestyle and in the impact of environmental factors in Western countries and a decreasing exposure to dietary aflatoxins and improved socio-economic conditions in developing countries will create new HCC epidemiology in the next few decades.
CONCLUSION: A substantial further reduction in cases of HCC requires a wider application of universal HBV vaccination and effective treatment of HBV- and HCV-related chronic hepatitis and cirrhosis, more effective campaigns to favor correct dietary habits and reduce alcohol consumption and the intensification of studies on HCC pathogenesis for future optimized prevention strategies.

Entities:  

Keywords:  Alcohol; Epidemiology; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; NAFLD; NASH

Mesh:

Year:  2019        PMID: 31347138     DOI: 10.1007/s15010-019-01345-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  103 in total

1.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Authors:  Reem Waziry; Behzad Hajarizadeh; Jason Grebely; Janaki Amin; Matthew Law; Mark Danta; Jacob George; Gregory J Dore
Journal:  J Hepatol       Date:  2017-08-09       Impact factor: 25.083

3.  Statin use and risk of liver cancer: Evidence from two population-based studies.

Authors:  Kim Tu Tran; Úna C McMenamin; Helen G Coleman; Chris R Cardwell; Peter Murchie; Lisa Iversen; Amanda J Lee; Aaron P Thrift
Journal:  Int J Cancer       Date:  2019-06-04       Impact factor: 7.396

4.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

5.  Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.

Authors:  Federico Piñero; Manuel Mendizabal; Ezequiel Ridruejo; Fernando Herz Wolff; Beatriz Ameigeiras; Margarita Anders; María Isabel Schinoni; Virginia Reggiardo; Ana Palazzo; María Videla; Cristina Alonso; Luisa Santos; Adriana Varón; Sebastián Figueroa; Cecilia Vistarini; Raúl Adrover; Nora Fernández; Daniela Perez; Federico Tanno; Nelia Hernández; Marcela Sixto; Silvia Borzi; Andres Bruno; Daniel Cocozzella; Alejandro Soza; Valeria Descalzi; Claudio Estepo; Alina Zerega; Alexandre de Araujo; Hugo Cheinquer; Marcelo Silva
Journal:  Liver Int       Date:  2019-02-04       Impact factor: 5.828

6.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Authors:  J A Davila; R O Morgan; Y Shaib; K A McGlynn; H B El-Serag
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies.

Authors:  Changhong Yi; Zhenggui Song; Maolin Wan; Ya Chen; Xiang Cheng
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

8.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

9.  Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.

Authors:  Federico Piñero; Josefina Pages; Sebastián Marciano; Nora Fernández; Jorge Silva; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Manuel Cobos; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  World J Hepatol       Date:  2018-01-27

10.  Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT.

Authors:  Linlin Yan; Yongqiong Deng; Jiyuan Zhou; Hong Zhao; Guiqiang Wang
Journal:  Infection       Date:  2018-03-29       Impact factor: 3.553

View more
  49 in total

1.  Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation.

Authors:  Jonathan Tefera; Margarita Revzin; Julius Chapiro; Lynn Jeanette Savic; David Mulligan; Ramesh Batra; Tamar Taddei; Dhanpat Jain; Xuchen Zhang
Journal:  J Clin Pathol       Date:  2020-05-19       Impact factor: 3.411

2.  Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3.

Authors:  Jia Zhang; Zhou Liu; Lingpeng Liu; Mingwen Huang; Yong Huang
Journal:  Cytotechnology       Date:  2022-02-22       Impact factor: 2.058

3.  Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development.

Authors:  Eman Saad Nassar; Yomna Abdelrazek Elkalbashawy; Ahmed Kamal; Nermine Hossam Eldin Zakaria
Journal:  Clin Exp Hepatol       Date:  2021-03-15

Review 4.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

5.  Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.

Authors:  Jian Pu; Xianjian Wu; Yi Wu; Zesheng Shao; Chunying Luo; Qianli Tang; Jianchu Wang; Huamei Wei; Yuan Lu
Journal:  Aging (Albany NY)       Date:  2021-03-22       Impact factor: 5.682

Review 6.  Hepatitis C Virus Uses Host Lipids to Its Own Advantage.

Authors:  Malgorzata Sidorkiewicz
Journal:  Metabolites       Date:  2021-04-27

7.  Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma.

Authors:  Tanvir Hossain; Shahla Romal; Elisa De Crignis; Fabrizia Carofiglio; Panagiotis Moulos; Mir Mubashir Khalid; Shringar Rao; Ameneh Bazrafshan; Monique Ma Verstegen; Farzin Pourfarzad; Christina Koutsothanassis; Helmuth Gehart; Tsung Wai Kan; Robert-Jan Palstra; Charles Boucher; Jan Nm IJzermans; Meritxell Huch; Sylvia F Boj; Robert Vries; Hans Clevers; Luc Jw van der Laan; Pantelis Hatzis; Tokameh Mahmoudi
Journal:  Elife       Date:  2021-07-30       Impact factor: 8.140

8.  MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection.

Authors:  Peng Wang; Ying Li; Lu Li; Rong Zhong; Na Shen
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

9.  SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC.

Authors:  Fanzhi Meng; Jinghua Liu; Tao Lu; Lanlan Zang; Jing Wang; Qiang He; Aijin Zhou
Journal:  Mol Ther Oncolytics       Date:  2021-02-04       Impact factor: 7.200

10.  AURKB, CHEK1 and NEK2 as the Potential Target Proteins of Scutellaria barbata on Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis.

Authors:  Chaoyuan Huang; Hu Luo; Yuancheng Huang; Chongkai Fang; Lina Zhao; Peiwu Li; Chong Zhong; Fengbin Liu
Journal:  Int J Gen Med       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.